{
    "info": {
        "nct_id": "NCT03150862",
        "official_title": "A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma",
        "inclusion_criteria": "All participants\n\n1. Age ≥ 18 years old.\n2. Confirmed diagnosis of glioblastoma (WHO Grade IV).\n3. Agreement to provide archival tumor tissue for exploratory biomarker analysis\n4. Ability to undergo serial MRIs.\n5. Eastern Cooperative Oncology Group (ECOG) status ≤ 1.\n6. Adequate hematologic and end-organ function\n7. Females of childbearing potential and non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing.\n8. Ability to swallow whole capsules.\n\n   Participants in Arms A and B (not Arm C) must meet inclusion criteria # 9 - 11:\n9. No previous treatment for GBM except surgery.\n10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy or ≥28 days after an open biopsy or craniotomy with adequate wound healing.\n11. Documented unmethylated MGMT promoter status.\n\n    Participants in Arm C Escalation (Phase 1b) must meet inclusion criteria # 12 - 15:\n12. Documentation of MGMT promoter status\n13. No prior systemic chemotherapy other than TMZ for GBM.\n14. Histologically confirmed secondary glioblastoma\n15. Disease that is evaluable or measurable as defined by Response Assessment in Neuro-Oncology (RANO) criteria\n\n    Participants in Arm C Expansion (Phase 2), must meet criteria # 16 - 18:\n16. Histologically confirmed de novo (primary) glioblastoma with unequivocal first progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy\n17. Disease that is measurable as defined by RANO criteria\n18. Documentation of MGMT promoter status\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "All participants\n\n1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days prior to start of study treatment.\n2. Toxicity of ≥ Grade 2 from prior therapy.\n3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment.\n4. History of other active malignancies within 2 years with exception of (i) adequately treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii) localized adequately treated cancer with curative intent or malignancy diagnosed > 2 years ago with no evidence of disease and no treatment ≤ 2 years prior to study treatment.\n5. Active infection requiring systemic treatment.\n6. Known human immunodeficiency virus (HIV) or active viral hepatitis.\n7. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease, ventricular arrhythmia or Cerebrovascular Accident (CVA) ≤ 6 months prior to start of treatment.\n8. Active clinically significant gastrointestinal disease.\n9. Active bleeding disorder ≤ 6 months prior to start of treatment.\n10. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.\n11. Use of any medications or food known to be strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong inducers.\n12. Pregnant or nursing females.\n13. Significant intercurrent illness that may result in participant's death prior to death from glioblastoma.\n\n    Arms B and C Only:\n14. Known hypersensitivity to any component of TMZ or decarbazine (DTIC).\n15. Have hereditary problems of galactose intolerance\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "All participants",
            "criterions": [
                {
                    "exact_snippets": "All participants",
                    "criterion": "participant",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy or ≥28 days after an open biopsy or craniotomy with adequate wound healing.",
            "criterions": [
                {
                    "exact_snippets": "Able to start radiation therapy ≤ 49 days after surgery",
                    "criterion": "time from surgery to start of radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "maximum time",
                            "expected_value": {
                                "operator": "<=",
                                "value": 49,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to start radiation therapy ... ≥ 14 days after a biopsy",
                    "criterion": "time from biopsy to start of radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to start radiation therapy ... ≥28 days after an open biopsy or craniotomy",
                    "criterion": "time from open biopsy or craniotomy to start of radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with adequate wound healing",
                    "criterion": "wound healing",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants in Arm C Expansion (Phase 2), must meet criteria # 16 - 18:",
            "criterions": [
                {
                    "exact_snippets": "must meet criteria # 16 - 18",
                    "criterion": "criteria #16-18",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Documentation of MGMT promoter status",
            "criterions": [
                {
                    "exact_snippets": "Documentation of MGMT promoter status",
                    "criterion": "MGMT promoter status",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. No previous treatment for GBM except surgery.",
            "criterions": [
                {
                    "exact_snippets": "No previous treatment for GBM except surgery",
                    "criterion": "previous treatment for GBM",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "surgery"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Adequate hematologic and end-organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... end-organ function",
                    "criterion": "end-organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Documented unmethylated MGMT promoter status.",
            "criterions": [
                {
                    "exact_snippets": "Documented unmethylated MGMT promoter status",
                    "criterion": "MGMT promoter methylation status",
                    "requirements": [
                        {
                            "requirement_type": "methylation status",
                            "expected_value": "unmethylated"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. No prior systemic chemotherapy other than TMZ for GBM.",
            "criterions": [
                {
                    "exact_snippets": "No prior systemic chemotherapy other than TMZ for GBM.",
                    "criterion": "prior systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "TMZ for GBM"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Ability to undergo serial MRIs.",
            "criterions": [
                {
                    "exact_snippets": "Ability to undergo serial MRIs.",
                    "criterion": "ability to undergo serial MRIs",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Disease that is measurable as defined by RANO criteria",
            "criterions": [
                {
                    "exact_snippets": "Disease that is measurable as defined by RANO criteria",
                    "criterion": "disease measurability (RANO criteria)",
                    "requirements": [
                        {
                            "requirement_type": "measurability (RANO)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Histologically confirmed de novo (primary) glioblastoma with unequivocal first progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed de novo (primary) glioblastoma",
                    "criterion": "glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "de novo (primary)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unequivocal first progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy",
                    "criterion": "progressive disease after RT with concurrent/adjuvant TMZ chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "first progressive disease"
                        },
                        {
                            "requirement_type": "clarity of progression",
                            "expected_value": "unequivocal"
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "radiotherapy (RT)",
                                "concurrent/adjuvant temozolomide (TMZ) chemotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Females of childbearing potential and non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing.",
            "criterions": [
                {
                    "exact_snippets": "Females of childbearing potential ... must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing",
                    "criterion": "females of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months after last dosing"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing",
                    "criterion": "non-sterile males",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months after last dosing"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Ability to swallow whole capsules.",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow whole capsules.",
                    "criterion": "ability to swallow whole capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Eastern Cooperative Oncology Group (ECOG) status ≤ 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) status ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Histologically confirmed secondary glioblastoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed secondary glioblastoma",
                    "criterion": "secondary glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants in Arms A and B (not Arm C) must meet inclusion criteria # 9 - 11:",
            "criterions": [
                {
                    "exact_snippets": "Participants in Arms A and B (not Arm C) must meet inclusion criteria # 9 - 11",
                    "criterion": "inclusion criteria #9-11",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age ≥ 18 years old.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years old.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Agreement to provide archival tumor tissue for exploratory biomarker analysis",
            "criterions": [
                {
                    "exact_snippets": "Agreement to provide archival tumor tissue",
                    "criterion": "archival tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "agreement to provide",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for exploratory biomarker analysis",
                    "criterion": "exploratory biomarker analysis",
                    "requirements": [
                        {
                            "requirement_type": "purpose of tissue provision",
                            "expected_value": "exploratory biomarker analysis"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Documentation of MGMT promoter status",
            "criterions": [
                {
                    "exact_snippets": "Documentation of MGMT promoter status",
                    "criterion": "MGMT promoter status",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Confirmed diagnosis of glioblastoma (WHO Grade IV).",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of glioblastoma",
                    "criterion": "glioblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "(WHO Grade IV)",
                    "criterion": "glioblastoma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "WHO Grade IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Disease that is evaluable or measurable as defined by Response Assessment in Neuro-Oncology (RANO) criteria",
            "criterions": [
                {
                    "exact_snippets": "Disease that is evaluable or measurable as defined by Response Assessment in Neuro-Oncology (RANO) criteria",
                    "criterion": "disease status (evaluable or measurable)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "evaluable",
                                "measurable"
                            ]
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "Response Assessment in Neuro-Oncology (RANO) criteria"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. Active infection requiring systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic treatment",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arms B and C Only:",
            "criterions": [
                {
                    "exact_snippets": "Arms B and C Only:",
                    "criterion": "study arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": [
                                "Arm B",
                                "Arm C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined Inclusion/Exclusion criteria may apply.",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Pregnant or nursing females.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... females",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing females",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Known hypersensitivity to any component of TMZ or decarbazine (DTIC).",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component of TMZ",
                    "criterion": "hypersensitivity to any component of TMZ",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to any component of ... decarbazine (DTIC)",
                    "criterion": "hypersensitivity to any component of decarbazine (DTIC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... ≤ 4 weeks prior to start of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant other injury ≤ 4 weeks prior to start of study treatment",
                    "criterion": "significant other injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Active clinically significant gastrointestinal disease.",
            "criterions": [
                {
                    "exact_snippets": "Active clinically significant gastrointestinal disease",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Toxicity of ≥ Grade 2 from prior therapy.",
            "criterions": [
                {
                    "exact_snippets": "Toxicity of ≥ Grade 2 from prior therapy",
                    "criterion": "toxicity from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.",
            "criterions": [
                {
                    "exact_snippets": "Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.",
                    "criterion": "therapeutic anti-coagulation",
                    "requirements": [
                        {
                            "requirement_type": "need",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medication",
                            "expected_value": [
                                "heparin",
                                "warfarin",
                                "other anticoagulants"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Active bleeding disorder ≤ 6 months prior to start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active bleeding disorder ≤ 6 months prior to start of treatment.",
                    "criterion": "active bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to start of treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Use of any medications or food known to be strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong inducers.",
            "criterions": [
                {
                    "exact_snippets": "Use of any medications or food known to be strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors",
                    "criterion": "use of strong or moderate CYP3A inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of any medications or food known to be ... strong ... inducers",
                    "criterion": "use of strong CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease, ventricular arrhythmia or Cerebrovascular Accident (CVA) ≤ 6 months prior to start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active, clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any Class 3 or 4 cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ventricular arrhythmia",
                    "criterion": "ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Cerebrovascular Accident (CVA) ≤ 6 months prior to start of treatment",
                    "criterion": "cerebrovascular accident (CVA)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to start of treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Significant intercurrent illness that may result in participant's death prior to death from glioblastoma.",
            "criterions": [
                {
                    "exact_snippets": "Significant intercurrent illness that may result in participant's death prior to death from glioblastoma.",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "risk of death before glioblastoma",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Known human immunodeficiency virus (HIV) or active viral hepatitis.",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active viral hepatitis",
                    "criterion": "viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Have hereditary problems of galactose intolerance",
            "criterions": [
                {
                    "exact_snippets": "hereditary problems of galactose intolerance",
                    "criterion": "hereditary galactose intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "All participants",
            "criterions": [
                {
                    "exact_snippets": "All participants",
                    "criterion": "participant status",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days prior to start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy ... ≤21 days prior to start of study treatment.",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biologic therapy ... ≤21 days prior to start of study treatment.",
                    "criterion": "prior biologic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy ... ≤21 days prior to start of study treatment.",
                    "criterion": "prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational agents ≤21 days prior to start of study treatment.",
                    "criterion": "prior investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [
        {
            "line": "Participants in Arm C Escalation (Phase 1b) must meet inclusion criteria # 12 - 15:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "4. History of other active malignancies within 2 years with exception of (i) adequately treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii) localized adequately treated cancer with curative intent or malignancy diagnosed > 2 years ago with no evidence of disease and no treatment ≤ 2 years prior to study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of other active malignancies within 2 years",
                    "criterion": "history of other active malignancies",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or activity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of (i) adequately treated in situ cancer of the cervix",
                    "criterion": "in situ cancer of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of (ii) non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of (iii) localized adequately treated cancer with curative intent",
                    "criterion": "localized cancer with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "malignancy diagnosed > 2 years ago with no evidence of disease and no treatment ≤ 2 years prior to study treatment",
                    "criterion": "malignancy diagnosed > 2 years ago",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment within last 2 years",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}